UBS lowered the firm’s price target on Medtronic (MDT) to $90 from $104 and keeps a Neutral rating on the shares. The firm updated its model to reflect the diabetes separation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $95 from $103 at Truist
- 3 Dividend Aristocrat Stocks Set to Reign With 15%+ Returns, 04/14/2026
- Medtronic price target lowered to $120 from $125 at Mizuho
- Medtronic price target lowered to $106 from $108 at Evercore ISI
- Medtronic price target lowered to $110 from $117 at Citi